Safety, tolerability and metabolic effects of once weekly GL0034 (Utreglutide) in individuals with obesity: a multiple ascending dose study

被引：0
|
作者：
Thennati, R. [1 ]
Burade, V. [1 ]
Nagarajan, M. [1 ]
Shahi, P. [1 ]
Nagaraja, R. [1 ]
Agrawal, S. [1 ]
Duvauchelle, T. [2 ]
Garcia-Ocana, A. [3 ]
Rutter, G. [4 ,5 ]
Pratley, R. E. [6 ]
Thorens, B. [7 ]
Vilsboll, T. [8 ,9 ]
机构：
[1] Sun Pharmaceut Ind Ltd, Vadodara, India
[2] Phaster 1, Le Plessis Trevise, France
[3] Arthur Riggs Diabet & Metab Res Inst, Dept Mol & Cellular Endocrinol, Duarte, CA USA
[4] Imperial Coll London, Dept Metab, Digest, Reprod, London, England
[5] Univ Montreal, Crchum, Quebec City, PQ, Canada
[6] AdventHealth, Translat Res Inst Metab & Diabet, Orlando, FL USA
[7] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland
[8] Steno Diabet Ctr Copenhagen, Clin Res, Herlev, Denmark
[9] Univ Copenhagen, Copenhagen, Denmark
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
751
引用
收藏
页码：S359 / S360
页数：2
相关论文
共 50 条
  • [31] Safety, tolerability and treatment effectiveness of chronic hepatitis B patients with pradefovir: a phase 1b multiple ascending dose study
    Jingrui, L.
    Junqi, N.
    Yanhua, D.
    Ning, X.
    Xiaoxue, Z.
    Xiaojiao, L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S105 - S105
  • [32] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RG1678, A NOVEL GLYCINE REUPTAKE INHIBITOR: A MULTIPLE ASCENDING DOSE STUDY IN HEALTHY VOLUNTEERS.
    Boetsch, C.
    Hofmann, C.
    Martin-Facklam, M.
    Banken, L.
    Biedinger, U.
    Patat, A.
    Boutouyrie, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S57 - S57
  • [33] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF OXFENDAZOLE IN HEALTHY ADULTS IN AN OPEN LABEL PHASE 1 MULTIPLE ASCENDING DOSE AND FOOD EFFECT STUDY.
    Bach, T.
    Galbiati, S.
    Kennedy, J.
    Deye, G.
    Nomicos, E.
    Codd, E.
    Garcia, H.
    Horton, J.
    Gilman, R.
    Gonzalez, A.
    Winokur, P.
    An, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S17 - S17
  • [34] Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease
    Xu, Julia Z.
    Conrey, Anna
    Frey, Ingrid
    Nichols, James
    Menapace, Laurel A.
    Tumburu, Laxminath
    Lequang, Timothy
    Li, Quan
    Dunkelberger, Emily
    Henry, Eric
    Cellmer, Troy
    Iyer, Varsha
    Mangus, Heidi
    Kung, Charles
    Dang, Lenny
    Kosinski, Penelope A.
    Hawkins, Peter
    Jeffries, Neal
    Eaton, William
    Thein, Swee Lay
    BLOOD, 2020, 136
  • [35] Single Dose Safety, Tolerability, and Pharmacokinetics of AB-423 in Healthy Volunteers from the ongoing Single and Multiple Ascending Dose Study AB-423-001
    Eley, Timothy
    Caamano, Sofia
    Denning, Jill
    Sims, Karen
    Larouche, Richard
    Symonds, William
    Mendez, Patricia
    HEPATOLOGY, 2017, 66 : 490A - 490A
  • [36] A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
    Pereira, Maria J.
    Lundkvist, Per
    Kamble, Prasad G.
    Lau, Joey
    Martins, Julian G.
    Sjostrom, C. David
    Schnecke, Volker
    Walentinsson, Anna
    Johnsson, Eva
    Eriksson, Jan W.
    DIABETES THERAPY, 2018, 9 (04) : 1511 - 1532
  • [37] A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
    Maria J. Pereira
    Per Lundkvist
    Prasad G. Kamble
    Joey Lau
    Julian G. Martins
    C. David Sjöström
    Volker Schnecke
    Anna Walentinsson
    Eva Johnsson
    Jan W. Eriksson
    Diabetes Therapy, 2018, 9 : 1511 - 1532
  • [38] A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
    Haakon B Nygaard
    Allison F Wagner
    Garrett S Bowen
    Susan P Good
    Martha G MacAvoy
    Kurt A Strittmatter
    Adam C Kaufman
    Brian J Rosenberg
    Tomoko Sekine-Konno
    Pradeep Varma
    Kewei Chen
    Anthony J Koleske
    Eric M Reiman
    Stephen M Strittmatter
    Christopher H van Dyck
    Alzheimer's Research & Therapy, 7
  • [39] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE NOVEL CATHEPSIN K INHIBITOR, ONO-5334, IN POSTMENOPAUSAL WOMEN: AN ASCENDING SINGLE AND MULTIPLE DOSE PHASE I STUDY
    Nagase, S.
    Hashimoto, Y.
    Ohyama, M.
    Kuwayama, T.
    Deacon, S.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 339 - 339
  • [40] SAFETY, TOLERABILITY, AND PHARACOKINETICS OF THE ORAL S-NITROSOGLUTATHIONE REDUCTASE INHIBITOR N91115: A MULTIPLE ASCENDING-DOSE STUDY IN HEALTHY SUBJECTS
    Shoemaker, S.
    Madagere, A.
    Troha, J.
    Abbas, V
    Galloway, C.
    Elhard, M.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 313 - 314
12345